KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBT Margin (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBT Margin for 11 consecutive years, with 861.6% as the latest value for Q1 2025.

  • Quarterly EBT Margin changed N/A to 861.6% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 4680.87% through Dec 2025, changed N/A year-over-year, with the annual reading at 4680.87% for FY2025, N/A changed from the prior year.
  • EBT Margin for Q1 2025 was 861.6% at Xenon Pharmaceuticals, up from 28588.64% in the prior quarter.
  • The five-year high for EBT Margin was 228.88% in Q1 2022, with the low at 28588.64% in Q3 2022.
  • Average EBT Margin over 3 years is 4736.05%, with a median of 766.36% recorded in 2021.
  • Peak annual rise in EBT Margin hit 13440bps in 2022, while the deepest fall reached -2824086bps in 2022.
  • Over 3 years, EBT Margin stood at 671.13% in 2021, then crashed by -4160bps to 28588.64% in 2022, then soared by 97bps to 861.6% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 861.6%, 28588.64%, and 5820.52% for Q1 2025, Q3 2022, and Q2 2022 respectively.